Molex, Myriad Genetics, Texas Instruments, Intel and Qualcomm

CHICAGO--([ BUSINESS WIRE ])--[ Zacks Equity Research ] highlights Molex (Nasdaq: [ MOLX ]) as the Bull of the Day and Myriad Genetics Inc. (Nasdaq: [ MYGN ]) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Texas Instruments, Inc. (NYSE: [ TXN ]), Intel Corp. (Nasdaq: [ INTC ]) and Qualcomm Corp. (Nasdaq: [ QCOM ]).

Full analysis of all these stocks is available at [ http://at.zacks.com/?id=2678 ].

Here is a synopsis of all five stocks:

[ Bull of the Day ]:

Molex (Nasdaq: [ MOLX ]) is a leading supplier of electronic and electrical components. The company's third quarter earnings solidly beat the Zacks Consensus, and forward guidance was also encouraging, driven by the broad-based market recovery.

We see momentum in Molex's business, with many growth opportunities across multiple markets. The new products strategy, restructuring actions, end market and geographic diversification, as well as the strong balance sheet are other positives.

The past year has been challenging and there are some issues with respect to higher taxes, but we remain positive about Molex's prospects going forward. Consequently, we are reiterating our Outperform rating on MOLX shares.

[ Bear of the Day ]:

Myriad Genetics Inc.'s (Nasdaq: [ MYGN ]) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period.

Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the overall weakness in the economy. It has affected sales adversely in recent quarters.

The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. Consequently, we have downgraded the stock to Underperform.

Latest Posts on the Zacks [ Analyst Blog ]:

Earnings Scorecard: Texas Instruments

There were a large number of estimate revisions following Texas Instruments, Inc.a�s (NYSE: [ TXN ]) very strong first-quarter earnings announced on April 26, 2010.

Over the past 30 days, almost all of the 35 analysts covering the stock raised their estimates for the second and third quarters ending in June and September, respectively, as well as fiscal years 2010 and 2011. There were no downward revisions for any of these periods.

Thirty analysts raised their estimates for the June quarter, while 29 raised the same for the September quarter. Moreover, 32 analysts raised their estimates for fiscal year 2010, while 31 raised the estimates for the following year.

Analysts have forwarded a number of reasons for the positive revisions.

Most importantly, analysts feel that management has very successfully reduced focus on the commoditized wireless business (primarily basebands), turning instead to infrastructure-type markets with its analog/embedded processing product line. Management vision and an experienced Research & Development (R&D) team have made this possible. Analysts have noted that some of the competitors, for instance Intel Corp. (Nasdaq: [ INTC ]) and Qualcomm Corp. (Nasdaq: [ QCOM ]), have not been able to make similar adjustments. The refocus has enabled the company to play in markets characterized by more stable growth rates and stronger pricing.

Get the full analysis of all these stocks by going to [ http://at.zacks.com/?id=2649 ].

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the [ Analyst Blog ] provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks [ "Profit from the Pros" ] e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=7158 ].

About Zacks

Zacks.com is a property of [ Zacks Investment Research ], Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the [ Zacks Rank ], which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4582 ].

Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.

Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contributing Sources

Market Wire

N@N

Molex, Myriad Genetics, Texas Instruments, Intel and Qualcomm